Tokai Pharmaceuticals Initiates ARMOR Clinical Development Program for TOK-001; First Ever Multi-Target Investigational Drug for Prostate Cancer
11/10/2009 9:40:22 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC. CRPC is an advanced, difficult-to-treat form of prostate cancer that does not respond to prostate cancer therapies. Nearly all men initially diagnosed with prostate cancer eventually advance to CRPC. Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer related deaths among men in the U.S.
comments powered by